Trials / Completed
CompletedNCT01919710
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Tianjin SinoBiotech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.
Detailed description
A dosage climbing for the safety and efficacy studies for the neutropenia induced by chemotherapy cancer patients Repeat-dose studies for the safety and efficacy studied for the neutropenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rHSA/GCSF | for treatment of neutropenia |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-06-01
- Completion
- 2014-08-01
- First posted
- 2013-08-09
- Last updated
- 2015-06-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01919710. Inclusion in this directory is not an endorsement.